



Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Montpellier, May 5, 2026, 07:30am CET – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place on May 11-15, 2026, in Boston, United-States.

Laurent Desire, Head of Preclinical Development at Sensorion, will present the following presentation at the ASGCT meeting:

Presentation type: Poster Presentation

Title: Safety, biodistribution and efficacy of SENS-601, an AAV-based gene therapy treatment candidate for the autosomal recessive non-syndromic deafness 1A (DFNB1A)

Date: Tuesday, May 12, 2026

Time: 5pm to 6:30 pm ET

Room: Thomas M. Menino Convention & Exhibition Center (MCEC) Halls B2-C, Exhibit Level

Marina Dos Santos, DSP Manager at Sensorion, will present the following presentation at the ASGCT meeting:

Presentation type: Poster Presentation

Title: Development and scale-up of an enrichment step for a difficult-to-produce recombinant AAV serotype

Date: Tuesday, May 12, 2026

Time: 5pm to 6:30 pm ET

Room: Thomas M. Menino Convention & Exhibition Center (MCEC) Halls B2-C, Exhibit Level

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. GJB2-GT (SENS-601) is the Company's lead gene therapy program, targeting hearing loss related to mutations in the GJB2 gene to address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve the diagnosis of these underserved illnesses.

Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progressed in three Phase 2 proof of concept clinical study: firstly, in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing, with analysis completed in Q1 2026. Secondly, with partner Cochlear Limited, a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation, completed in 2024. Thirdly, a Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in 2022.

www.sensorion.com

Contacts

Investor Relations

Sensorion
Nicolas Bogler, Investor Relations and
Communication
ir.contact@sensorion-pharma.com

Press Relations

Maarc Communication
Bruno Arabian / 00 33(0)6 87 88 47 26
bruno.arabian@maarc.fr

Label: **SENSORION**
ISIN: **FR0012596468**
Mnemonic: **ALSEN**



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2025 full year report published on March 18, 2026, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.